Product logins

Find logins to all Clarivate products below.

home   •  Research Reports  •  Disease Landscape and Forecast Insights
$16,500.00   |  '

Spinal Cord Injury | Executive Insights | US | 2020

Login to access report north_east
Buy report north_east

Spinal cord injury (SCI) is a catastrophic event, often as a result of trauma, that typically results in long-lasting motor, sensory, and/or autonomic deficits. The nature of such deficits is dependent on the level of the spinal cord at which the injury occurs and the severity of damage to the cord at that level. Treatment involves nonpharmacological and pharmacological management of associated complications but no current therapy can restore function. The SCI pipeline consists of regenerative / reparative treatments, including several stem cell therapies, monoclonal antibodies against an axonal guidance molecule (AbbVie’s elezanumab, Mitsubishi Tanabe’s MT-3921), and an implantable scaffold that can facilitate axonal regrowth (InVivo Therapeutics’ Neuro-Spinal Scaffold). If these treatments launch, they have notable commercial potential because of the immense unmet need in this indication.

QUESTIONS ANSWERED

  • How are SCI patients categorized and to what extent does that categorization influence management of the SCI?
  • What are the key areas of unmet need and opportunity in SCI?
  • What pharmacological and nonpharmacological treatments are used to manage an SCI and what are the goals of such treatment?
  • What compounds are advancing through the SCI pipeline and how will their potential introduction change the SCI treatment paradigm in the acute, subacute, and/or chronic phases of treatment post-SCI?
  • What are the future players in this market, and what level of influence will they have on the future market?

PRODUCT DESCRIPTION

Executive Insights provides indication-specific market intelligence with world-class epidemiology, keen insight into current treatment paradigms, biotherapeutic pipelines, key clinical unmet needs, and competitive landscapes, supported by primary and secondary research. This solution provides succinct insights to any biopharma function or business professional looking to quickly grasp a new indication of interest.

Geography covered: United States

Primary research: Three interviews with neurosurgeons in the United States

Key companies covered: AbbVie, InVivo Therapeutics, Lineage Cell Therapeutics, Mayo Clinic, Mitsubishi Tanabe Pharma, StemCyte

Key products covered: Asclepios, AST-OPC1, elezanumab (ABT-555), MC-001, MT-3921, Neuro-Spinal Scaffold

Buy report north_east
Login to access report north_east

Related Market Assessment Reports

Report
Major Depressive Disorder (DSM-V) – Current Treatment – Treatment Algorithms: Claims Data Analysis – Major Depressive Disorder (US)
Major depressive disorder (MDD) is a condition heavily treated with an array of drug classes. Although the MDD drug market is dominated by generic therapies, the heterogeneous response of MDD…
north_east
Report
Hidradenitis Suppurativa – Current Treatment – Treatment Algorithms: Claims Data Analysis – Hidradenitis Suppurativa (US)
Hidradenitis suppurativa (HS) is a chronic, relapsing inflammatory disorder affecting hair follicles. It is characterized by the occurrence of inflamed and swollen lesions, which are typically…
north_east
Report
Obesity / Overweight – Geographic Focus: China – China In-Depth – Obesity / Overweight
Obesity is recognized as a chronic disease and public health crisis globally. The primary goal of treatment is to improve obese patients’ health outcomes and quality of life. Unlike other highly…
north_east
Report
Gastroesophageal Cancer – Geographic Focus: China – China In-Depth – Gastroesophageal cancer
China accounts for nearly half of the cases of gastroesophageal cancer in the world, and its incidence there is expected to increase due to urbanization and an aging population. Current treatment…
north_east
Report
Immunoglobulin A Nephropathy – Access & Reimbursement – Access & Reimbursement – Immunoglobulin A Nephropathy (US)
The U.S. IgA nephropathy (IgAN) therapy market predominantly comprises supportive treatments such as RAAS inhibitors, SGLT-2 inhibitors, immunosuppressants, and/or diuretics. The FDA’s acceptance…
north_east

Follow us

Contact us

Sales enquiries north_east
Customer service north_east
Support north_east